Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Jefferson Researcher’s Results Show Promise for Metastatic Eye Melanoma

18.05.2005


Boosting the immune system, cutting off tumor oxygen supply, may be keys to patients living longer



When melanoma of the eye spreads to the liver, patients have few good options. Surgery is frequently impossible, and chemotherapy hasn’t proven effective. But now, by simultaneously revving up the immune system and choking off the tumor’s oxygen supply, oncologists at Jefferson Medical College and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia may have found a better way to battle this deadly cancer.

Researchers, led by Takami Sato, M.D., K. Hasumi Associate Professor of Medicine at Jefferson Medical College of Thomas Jefferson University, have shown promising results from an early, phase 1-2 clinical trial of a novel treatment for uveal melanoma that has spread to the liver.


In the procedure, called immunoembolization, Dr. Sato and his co-workers “embolize,” or block off the hepatic artery, which is a major artery feeding the liver, cutting off oxygen to liver tumors. They infuse a chemical called GM-CSF, which stimulates the immune system – specifically, cells called macrophages and dendritic cells – to produce an inflammatory reaction, and it’s hoped, fight the cancer.

In the trial, which was aimed at testing for treatment toxicity and feasibility, Dr. Sato found that 30 percent of 39 patients studied (34 of whom had uveal melanoma) had tumor shrinkage and another 30 percent had tumors that didn’t grow.

He presents his team’s findings May 17, 2005 at the annual meeting of the American Society of Clinical Oncology in Orlando.

“We have seen a surprising phenomenon,” he says. “Compared to chemoembolization (a similar, older therapy that entails giving a patient chemotherapy directly into the liver), our patients did just as well and some did better. The treatment is doing something to prolong survival.

“If we’re right,” Dr. Sato says, “we could delay metastases.”

Dr. Sato also found a response in other tumors in the body besides the liver – a potentially important finding, he says. Patients in the study lived on average about twice as long compared to those who received chemoembolization in an earlier study he and his team conducted.

Dr. Sato heads one of the few programs in the nation treating metastatic uveal melanoma, which is a melanoma originating in the eye and the most common adult eye tumor. It is very rare, affecting perhaps 6 or 7 individuals per 1 million. When it spreads to the liver, patients who do not receive treatment live on average about 6 months. The treatment Dr. Sato is testing is used for patients who are not eligible for surgery.

While the trial results show the two-pronged treatment is safe and feasible – as well as providing promising responses to metastases, Dr. Sato reaffirms the need for a larger phase 2 study, which has already opened for patients with uveal melanoma metastatic to the liver. The phase 2 trial compares immunoembolization to embolization, or cutting off the tumor’s oxygen supply. The trial is funded by an R21 grant for nearly $600,000 over two years that he recently received from the National Cancer Institute.

In the new trial, he will also monitor the immune system reaction, looking for an increase in numbers of specific immune cells. He plans to biopsy patient livers, he notes, because “If the GM-CSF is working, an inflammatory response should be seen in the liver tumor.”

The next step in the future, he says, would be to conduct a phase 3 multicenter trial comparing chemoembolization and immunoembolization. He notes that the immunoembolization procedure may be useful in treating primary liver cancer or other types of cancer that have spread to the liver as well.

Steve Benowitz | EurekAlert!
Further information:
http://www.jefferson.edu

More articles from Health and Medicine:

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

nachricht Disrupted fat breakdown in the brain makes mice dumb
19.05.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

Im Focus: Bacteria harness the lotus effect to protect themselves

Biofilms: Researchers find the causes of water-repelling properties

Dental plaque and the viscous brown slime in drainpipes are two familiar examples of bacterial biofilms. Removing such bacterial depositions from surfaces is...

Im Focus: Hydrogen Bonds Directly Detected for the First Time

For the first time, scientists have succeeded in studying the strength of hydrogen bonds in a single molecule using an atomic force microscope. Researchers from the University of Basel’s Swiss Nanoscience Institute network have reported the results in the journal Science Advances.

Hydrogen is the most common element in the universe and is an integral part of almost all organic compounds. Molecules and sections of macromolecules are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

Innovation 4.0: Shaping a humane fourth industrial revolution

17.05.2017 | Event News

Media accreditation opens for historic year at European Health Forum Gastein

16.05.2017 | Event News

 
Latest News

New approach to revolutionize the production of molecular hydrogen

22.05.2017 | Materials Sciences

Scientists enlist engineered protein to battle the MERS virus

22.05.2017 | Life Sciences

Experts explain origins of topographic relief on Earth, Mars and Titan

22.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>